This trial is evaluating whether KSP/QRH dimer will improve 4 primary outcomes in patients with Barrett Esophagus. Measurement will happen over the course of 2 years.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. KSP/QRH Dimer is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"There is currently insufficient evidence to show that lifestyle factors predispose individuals to BE. However, some evidence indicates that lifestyle factors, such as smoking and alcohol consumption, may increase the risk of BE." - Anonymous Online Contributor
"About 600 people in the United States die a year in hospitals due to untreated Barrett esophagus. Many people are already diagnosed with early-stage Barrett esophagus. These patients may benefit from treatment of other comorbid disorders with the ultimate goal of achieving and maintaining remission of Barrett esophagus." - Anonymous Online Contributor
"Barrett esophagus is a form of reflux esophagitis that can lead to esophageal adenocarcinoma (the cancer of the esophagus). Esophageal adenocarcinoma is the third most frequent cause of death from cancer in the USA. In some parts of the USA, approximately 35% of esophageal adenocarcinomas are attributed to Barrett esophagus. In contrast to other cancers, it is rarely diagnosed at an early stage. In most populations Barrett esophagus accounts for an average of 60% of esophageal cancers." - Anonymous Online Contributor
"The current treatment options for benign esophageal varices are inadequate and the development of new therapeutic options is needed. New therapeutic approaches should target the underlying cause to halt or reverse the progression of BEV. Barrera, W." - Anonymous Online Contributor
"Patients with Barrett's esophagus do not develop signs of Barrett's from esophageal biopsy, though there is high prevalence of associated dysplasia and adenocarcinoma. Barrett's esophagus is a long and gradual disease, and symptomatic patients are often found much later than those with a metaplastic dysplastic component. Barrett's esophagus should therefore be considered as a complication of gastro-oesophageal reflux." - Anonymous Online Contributor
"Data from a recent study suggests that the treatment of BE is associated with a higher rate of mortality than that of non-RE patients. Although RE and non-RE patient survival and mortality rates are similar. After 5 years, survival of RE patients was better than that of the non-RE patients because the RE patients were older. This is the first study to report on the cure rate of BE. The current research may encourage further clinical and basic research on the pathogenesis, the treatment, and the prevention of BE." - Anonymous Online Contributor
"It is important to know the most common side effects of ksp/qrh dimer, to avoid unnecessary concerns, and decide whether or not to continue the treatment. In addition, the most common side effects of ksp/qrh dimer are nausea, stomach upset, vomiting, diarrhoea, dizziness, constipation, and drowsiness. Symptoms may occur in the first few weeks of treatment, but usually subsides during the following weeks. It is very important to tell your doctor if the symptoms in the first few weeks of treatment are too debilitating or if you have trouble performing daily activities. Once those symptoms diminish, tell your doctor when symptoms from the medication might interfere with eating, sleeping, or exercise." - Anonymous Online Contributor
"Therapeutic use of Ksp/Qrh dimer resulted in reduced leakage, improved esophageal perfusion and decreased esophageal collagen deposition. The therapeutic use of Ksp/Qrh dimer in patients with Barrett's esophagus was associated with significant improvement in quality of life." - Anonymous Online Contributor
"In this retrospective analysis, Ksp/qRh dimer combination use is not associated with an improvement in pathological response to neoadjuvant chemoradiotherapy. In selecting patients and treatment schedule, this combination may also be explored as a monotherapy." - Anonymous Online Contributor
"[It was the primary finding that the esophageal strictures in the BE group were mostly found at an early age and on the right side of the esophagus.](https://clinjournals.cdlib.org/article/10.1614/cdlj.2017-12-22." - Anonymous Online Contributor
"This is a novel Ksp (KS) dimer of unknown function. We suggest that it plays a role in determining the level of cytotoxicity as well as inducing apoptosis through a mechanism involving phosphorylation of Ser-531 and Ser-537 in the C terminus. The presence of this peptide may have been responsible for the development of Barrett's esophagus after tracheal intubation." - Anonymous Online Contributor
"This review shows that the understanding of the pathogenesis of BE has greatly advanced. In the near future, investigations of the effectiveness of medical therapies and pharmacological approaches to treat BE and to prevent CE in patients with BE will be conducted. With the successful progress made during the past decade, it seems unlikely that BE will be as mysterious as it once was or that BE-related health care cost savings can occur as they have, thereby furthering the public health agenda toward better, early diagnosis and more successful treatment." - Anonymous Online Contributor